1
|
Fruscalso V, Olmos G, Hötzel M. Dairy calves’ mortality survey and associated management practices in smallholding, pasture-based herds in southern Brazil. Prev Vet Med 2020; 175:104835. [DOI: 10.1016/j.prevetmed.2019.104835] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 11/08/2019] [Accepted: 11/08/2019] [Indexed: 01/04/2023]
|
2
|
de Vega A, Valiente OL, Olmos G, Pérez-Calvo E. Use of barley crops, and combinations of lucerne and Wimmera grass, as pasture for grazing sheep in the semiarid zones of Spain. Anim Prod Sci 2018. [DOI: 10.1071/an16788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Taking into account the relationship between rainfall and temperature, 64% of the Spanish territory can be classified as arid (25%) or semiarid (39%). In these areas, vegetal surface includes permanent pastures and drought grasslands (34.0%), fallows (13.4%), winter cereals for grain production (21.2%), forage crops (mainly lucerne, and winter cereals harvested as green forage; 2.6%) and woodland hills. Ruminants in these zones account for 15.4 million head, of which nearly 80% are sheep. In the present paper, the possibilities of integrating sheep in cropping systems are discussed, and an alternative based on the use of permanent sowed prairies (lucerne), self-sowing annuals (Wimmera ryegrass) and winter cereals (barley) will be analysed.
Collapse
|
3
|
Pol Fuster J, Ruiz Guerra L, Ortega Vila B, Medina Dols A, Bisbal Carrió B, Lladó J, Olmos G, Heine Suñer D, Cañellas F, Vives Bauzà C. Identification of Novel Genes Associated to Major Mental Disease by Whole Exome Sequencing in Families with High Prevalence. Eur Psychiatry 2017. [DOI: 10.1016/j.eurpsy.2017.01.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
IntroductionThe identification of new genetic variants underlying psychosis is crucial to improve its molecular diagnosis and to determine the disease etiology, which is necessary to develop new therapeutic targets.AimTo identify novel rare genetic variants associated to mental disorders, using whole exome sequencing (WES).MethodsTwo families with high prevalence of mental disease were genotyped using WES. The first family has 5 members affected, the mother with a bipolar disorder, three sons, two with schizophrenia and one with schizoaffective disorder, and a cousin with major depression and psychotic symptoms. The second family is constituted by 38 members affected by major mental diseases in three generations. Key affected members of each family were genotyped by WES. Shared rare variants, with allelic frequencies below 0.5% in general population, were identified among the affected members of the family. The segregation of those variants was confirmed by Sanger sequencing.ResultsIn family 1, thirty-seven genetic variants related to neurodevelopment were identified. Two of those variants in the genes TRIP12 and RNF25 segregated with psychosis. In family 2, seven rare genetic variants contained in genes related to neurodevelopment were identified. A mutation in the gene ARHGAP19 segregated with psychosis.ConclusionsThree new genes have been found to be associated with psychosis. TRIP12 and RNF25 encode two E3-ubiquitin ligases which modulate the Wnt pathway, mutations in which lead to neurodevelopmental defects. ARHGAP19 encodes a GTPase which regulates the RhoA protein, involved in the regulation of the cytoskeleton.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
4
|
Gonzalez-Ramos M, de Frutos S, Griera M, Luengo A, Olmos G, Rodriguez-Puyol D, Calleros L, Rodriguez-Puyol M. Integrin-linked kinase mediates the hydrogen peroxide-dependent transforming growth factor-β1 up-regulation. Free Radic Biol Med 2013; 61:416-27. [PMID: 23624332 DOI: 10.1016/j.freeradbiomed.2013.04.029] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 03/21/2013] [Accepted: 04/17/2013] [Indexed: 01/04/2023]
Abstract
Transforming growth factor type-β1 (TGF-β1) has been recognized as a central mediator in many pathological events related to extracellular matrix (ECM) proteins accumulation, where their locally increased expression has been implicated in the fibrosis process of numerous organs, including glomerular fibrosis in the kidney. We and others have reported the TGF-β1 synthesis regulation by reactive oxygen species (ROS), and moreover we also described the implication of integrin-linked kinase (ILK) in the AP-1-dependent TGF-β1 up-regulation. Thus, we propose here that hydrogen peroxide (H2O2)-dependent TGF-β1 regulation may be mediated by ILK activation. First we confirmed the increase in TGF-β1 expression in human mesangial cells (HMC) after treatment with H2O2 or with an alternative H2O2-generating system such as the glucose-oxidase enzyme (GOX). By using immunoblotting, immunofluorescence, and ELISA techniques, we demonstrate that extracellular H2O2 up-regulates TGF-β1 transcription, as well as increases TGF-β1 promoter activity. Furthermore, catalase-decreased intracellular H2O2 abolished TGF-β1 up-regulation. The use of pharmacological inhibitors as well as knockdown of ILK with small interfering RNA (siRNA) demonstrated the implication of a PI3K/ILK/AKT/ERK MAPK signaling pathway axis in the H2O2-induced TGF-β1 overexpression. Finally, we explored the physiological relevance of these findings by treating HMC with angiotensin II, a known stimuli of H2O2 synthesis. Our results confirm the relevance of previous findings after a more physiological stimulus. In summary, our results provide evidence that ILK activity changes may act as a mechanism in response to different stimuli such as H2O2 in the induced TGF-β1 up-regulation in pathological or even physiological conditions.
Collapse
Affiliation(s)
- M Gonzalez-Ramos
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain
| | - S de Frutos
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain
| | - M Griera
- IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain; Biomedical Research Unit Foundation, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - A Luengo
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain
| | - G Olmos
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain
| | - D Rodriguez-Puyol
- IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain; Department of Medicine, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; Nephrology Section, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - L Calleros
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain.
| | - M Rodriguez-Puyol
- Department of Physiology, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain; IRSIN, Madrid, Spain; RedInRen (Instituto de Salud Carlos III), Madrid, Spain
| |
Collapse
|
5
|
Cerini C, Gondouin B, Dou L, Duval-Sabatier A, Brunet P, Dignat- George F, Burtey S, Okano K, Okano K, Iwasaki T, Jinnai H, Hibi A, Miwa N, Kimata N, Nitta K, Akiba T, Dolley-Hitze T, Verhoest G, Jouan F, Arlot-Bonnemains Y, Lavenu A, Belaud-Rotureau MA, Rioux-Leclercq N, Vigneau C, Cox SN, Sallustio F, Serino G, Loverre A, Pesce F, Gigante M, Zaza G, Stifanelli P, Ancona N, Schena FP, Marc P, Jacques T, Green JM, Mortensen RB, Verma R, Leu K, Schatz PJ, Wojchowski DM, Ihoriya C, Satoh M, Sasaki T, Kashihara N, Jung YJ, Kang KP, Lee AS, Lee JE, Lee S, Park SK, Kim W, Kang KP, Florian T, Tepel M, Ying L, Katharina K, Nora F, Antje W, Alexandra S, Chiu YT, Wu MJ, Liu ZH, Liang Y, Zheng CX, Chen ZH, Zeng CH, Ranzinger J, Rustom A, Kihm L, Heide D, Scheurich P, Zeier M, Schwenger V, Liu J, Liu J, Zhong F, Xu L, Zhou Q, Hao X, Wang W, Chen N, Zhong F, Zhong F, Liu X, Zhou Q, Hao X, Lu Y, Guo S, Wang W, Lin D, Chen N, Vilasi A, Deplano S, Deplano S, Cutillas P, Unwin R, Tam FWK, Medrano-Andres D, Lopez-Martinez V, Martinez-Miguel P, Cano JL, Arribas I, Rodiguez-Puyol M, Lopez-Ongil S, Kadoya H, Nagasu H, Satoh M, Sasaki T, Kashihara N, Lindeberg E, Grundstrom G, Alexandra S, Tepel M, Katharina K, Alexandra M, Ghosh CC, David S, Mukherjee A, John SG, Mcintyre CW, Haller H, Parikh SM, Troyano N, Del Nogal M, Olmos G, Mora I, DE Frutos S, Rodriguez-Puyol M, Ruiz MP, Rothe H, Rothe H, Shapiro W, Ketteler M, Ramakrishnan SK, Loupy A, Houillier P, Guilhermino Pereira L, Boim M, Aragao D, Casarini D, Jin Y, Jin Y, Chen N, Moon JY, Kim YG, Lee SH, Lee TW, Ihm CG, Kim EY, Lee HJ, Wi JG, Jeong KH, Ruan XZ, LI LC, Varghese Z, Chen JB, Lee CT, Moorhead J, Dou L, Gondouin B, Cerini C, Poitevin S, Brunet P, Dignat-George F, Stephane B, Bonanni A, Verzola D, Maggi D, Brunori G, Sofia A, Mannucci I, Maffioli S, Salani B, D'amato E, Saffioti S, Laudon A, Cordera R, Garibotto G, Maquigussa E, Boim M, Arnoni C, Guilhermino Pereira L. Cell signalling / Pathophysiology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Yi Chun DX, Alexandre H, Edith B, Nacera O, Julie P, Chantal J, Eric R, Zhang X, Jin Y, Miravete M, Dissard R, Klein J, Gonzalez J, Caubet C, Pecher C, Pipy B, Bascands JL, Mercier-Bonin M, Schanstra J, Buffin-Meyer B, Claire R, Rigothier C, Richard D, Sebastien L, Moin S, Chantal B, Christian C, Jean R, Migliori M, Migliori M, Cantaluppi V, Mannari C, Medica D, Giovannini L, Panichi V, Goldwich A, Alexander S, Andre G, Amann K, Migliorini A, Sagrinati C, Angelotti ML, Mulay SR, Ronconi E, Peired A, Romagnani P, Anders HJ, Chiang WC, Lai CF, Peng WH, Wu CF, Chang FC, Chen YT, Lin SL, Chen YM, Wu KD, Lu KS, Tsai TJ, Virgine O, Qing Feng F, Zhang SY, Dominique D, Vincent A, Marina C, Philippe L, Georges G, Pawlak A, Sahali D, Matsumoto S, Kiyomoto H, Ichimura A, Dan T, Nakamichi T, Tsujita T, Akahori K, Ito S, Miyata T, Xie S, Zhang B, Shi W, Yang Y, Nagasu H, Satoh M, Kidokoro K, Nishi Y, Ihoriya C, Kadoya H, Sasaki T, Kashihara N, Wu CF, Chang FC, Chen YT, Chou YH, Duffield J, Lin SL, Rocca C, Rocca C, Gregorini M, Corradetti V, Valsania T, Bedino G, Bosio F, Pattonieri EF, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Bedino G, Gregorini M, Corradetti V, Rocca C, Pattonieri EF, Valsania T, Bosio F, Esposito P, Sepe V, Libetta C, Rampino T, Dal Canton A, Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H, Wasilewska A, Taranta-Janusz K, Deebek W, Kuroczycka-Saniutycz E, Lee AS, Lee AS, Lee JE, Jung YJ, Kang KP, Lee S, Kim W, Arfian N, Emoto N, Yagi K, Nakayama K, Hartopo AB, Nugrahaningsih DA, Yanagisawa M, Hirata KI, Munoz-Felix JM, Lopez-Novoa JM, Martinez-Salgado C, Oujo B, Munoz-Felix JM, Arevalo M, Bernabeu C, Perez-Barriocanal F, Lopez-Novoa JM, Jesper K, Nathalie V, Pierre G, Yi Chun DX, Alexandre H, Eric R, Iyoda M, Shibata T, Matsumoto K, Shindo-Hirai Y, Kuno Y, Wada Y, Akizawa T, Schwartz I, Schwartz D, Prot Bertoye C, Prot Bertoye C, Terryn S, Claver J, Beghdadi WB, Monteiro R, Blank U, Devuyst O, Daugas E, Van Beneden K, Geers C, Pauwels M, Mannaerts I, Van den Branden C, Van Grunsven LA, Seckin I, Pekpak M, Uzunalan M, Uruluer B, Kokturk S, Ozturk Z, Sonmez H, Yaprak E, Furuno Y, Tsutsui M, Morishita T, Shimokawa H, Otsuji Y, Yanagihara N, Kabashima N, Ryota S, Kanegae K, Miyamoto T, Nakamata J, Ishimatsu N, Tamura M, Nakagawa T, Nakagawa T, Ichikawa K, Miyamoto M, Takabayashi D, Yamazaki H, Kakeshita K, Koike T, Kagitani S, Tomoda F, Hamashima T, Ishii Y, Inoue H, Sasahara M, El Machhour F, Kerroch M, Mesnard L, Chatziantoniou C, Dussaule JC, Inui K, Sasai F, Maruta Y, Nishiwaki H, Kawashima E, Inoue Y, Yoshimura A, Matsumoto K, Matsumoto K, Iyoda M, Shibata T, Wada Y, Shindo-Hirai Y, Kuno Y, Akizawa T, Musacchio E, Priante G, Valvason C, Sartori L, Baggio B, Kim JH, Gross O, Diana R, Gry DH, Asimal B, Johanna T, Imke SE, Lydia W, Gerhard-Anton M, Hassan D, Cano JL, Griera M, Olmos G, Martin P, Cortes MA, Lopez-Ongil S, Rodriguez-Puyol D, DE Frutos S, Gonzalez M, DE Frutos S, Cano JL, Luengo A, Martin P, Rodriguez-Puyol M, Calleros L, Lupica R, Lacquaniti A, Donato V, Maggio R, Mastroeni C, Lucisano S, Cernaro V, Fazio MR, Quartarone A, Buemi M, Kacik M, Goedicke S, Eggert H, Hoyer JD, Wurm S, Wurm S, Steege A, Banas M, Kurtz A, Banas B, Lasagni L, Lazzeri E, Peired A, Angelotti ML, Ronconi E, Romoli S, Romagnani P, Schaefer I, Teng B, Worthmann K, Haller H, Schiffer M, Prattichizzo C, Netti GS, Rocchetti MT, Cormio L, Carrieri G, Stallone G, Grandaliano G, Ranieri E, Gesualdo L, Kucher A, Smirnov A, Parastayeva M, Beresneva O, Kayukov I, Zubina I, Ivanova G, Abed A, Schlekenbach L, Foglia B, Chatziantoniou C, Kwak B, Chadjichristos C, Queisser N, Schupp N, Brand S, Himer L, Himer L, Szebeni B, Sziksz E, Saijo S, Kis E, Prokai A, Banki NF, Fekete A, Tulassay T, Vannay A, Hegner B, Schaub T, Lange C, Dragun D, Klinkhammer BM, Rafael K, Monika M, Anna M, Van Roeyen C, Boor P, Eva Bettina B, Simon O, Esther S, Floege J, Kunter U, Hegner B, Janke D, Schaub T, Lange C, Jankowski J, Dragun D, Hayashi M, Takamatsu I, Horimai C, Yoshida T, Seno DI Marco G, Koenig M, Stock C, Reiermann S, Amler S, Koehler G, Fobker M, Buck F, Pavenstaedt H, Lang D, Brand M, Plotnikov E, Morosanova M, Pevzner I, Zorova L, Pulkova N, Zorov D, Wornle M, Ribeiro A, Belling F, Merkle M, Nakazawa D, Nishio S, Shibasaki S, Tomaru U, Akihiro I, Kobayashi I, Imanishi Y, Kurajoh M, Nagata Y, Yamagata M, Emoto M, Michigami T, Ishimura E, Inaba M, Nishi Y, Satoh M, Sasaki T, Kashihara N, Wu CC, Lu KC, Chen JS, Chu P, Lin YF, Eller K, Schroll A, Banas M, Kirsch A, Huber J, Weiss G, Theurl I, Rosenkranz AR, Zawada A, Rogacev K, Achenbach M, Fliser D, Held G, Heine GH, Miyamoto Y, Iwao Y, Watanabe H, Kadowaki D, Ishima Y, Chuang VTG, Sato K, Otagiri M, Maruyama T, Ueda Y, Iwatani H, Isaka Y, Watanabe H, Honda D, Miyamoto Y, Noguchi T, Kadowaki D, Ishima Y, Tanaka M, Tanaka H, Fukagawa M, Otagiri M, Maruyama T, Wornle M, Ribeiro A, Pircher J, Koppel S, Mannell H, Krotz F, Merkle M, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Virzi GM, Bolin C, Cruz D, Scalzotto E, De Cal M, Vescovo G, Ronco C, Grobmayr R, Lech M, Ryu M, Anders HJ, Aoshima Y, Mizobuchi M, Ogata H, Kumata C, Nakazawa A, Kondo F, Ono N, Koiwa F, Kinugasa E, Akizawa T, Freisinger W, Lale N, Lampert A, Ditting T, Heinlein S, Schmieder RE, Veelken R, Nave H, Perthel R, Suntharalingam M, Bode-Boger S, Beutel G, Kielstein J, Rodrigues-Diez R, Rodrigues-Diez R, Rayego-Mateos S, Lavoz C, Stark Aroeira LG, Orejudo M, Alique M, Ortiz A, Egido J, Ruiz-Ortega M, Oskar W, Rusan C, Schaub T, Hegner B, Dragun D, Padberg JS, Wiesinger A, Brand M, Seno DI Marco G, Reuter S, Grabner A, Kentrup D, Lukasz A, Oberleithner H, Pavenstadt H, Kumpers P, Eberhardt HU, Skerka C, Chen Q, Hallstroem T, Hartmann A, Kemper MJ, Zipfel PF, N'gome-Sendeyo K, Fan QF, Zhang SY, Pawlak A, Sahali D, Wornle M, Ribeiro A, Merkle M, Toblli J, Toblli J, Cao G, Giani JF, Dominici FP, Kim JS, Yang JW, Kim MK, Han BG, Choi SO. Experimental pathology. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
O’Driscoll K, Olmos G, Llamas Moya S, Mee J, Earley B, Gleeson D, O’Brien B, Boyle L. A reduction in milking frequency and feed allowance improves dairy cow immune status. J Dairy Sci 2012; 95:1177-87. [DOI: 10.3168/jds.2011-4408] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2011] [Accepted: 10/28/2011] [Indexed: 11/19/2022]
|
8
|
Mir M, Asensio VJ, Tolosa L, Gou-Fabregas M, Soler RM, Lladó J, Olmos G. Tumor necrosis factor alpha and interferon gamma cooperatively induce oxidative stress and motoneuron death in rat spinal cord embryonic explants. Neuroscience 2009; 162:959-71. [PMID: 19477238 DOI: 10.1016/j.neuroscience.2009.05.049] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2009] [Revised: 05/15/2009] [Accepted: 05/21/2009] [Indexed: 12/13/2022]
Abstract
The accumulation of reactive microglia in the degenerating areas of amyotrophic lateral sclerosis (ALS) tissue is a key cellular event creating a chronic inflammatory environment that results in motoneuron death. We have developed a new culture system that consists in rat spinal cord embryonic explants in which motoneurons migrate outside the explant, growing as a monolayer in the presence of glial cells. The proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma) have been proposed to be involved in ALS-linked microglial activation. In our explants, the combined exposure to these cytokines resulted in an increased expression of the pro-oxidative enzymes inducible nitric oxide synthase (iNOS), the catalytic subunit of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, gp91(phox) and cyclooxygenase-2 (COX-2), as compared to each cytokine alone. This effect was related to their cooperation in the activation of the transcription factor nuclear factor kappa B (NF-kappaB). TNF-alpha and IFN-gamma also cooperated to promote protein oxidation and nitration, thus increasing the percentage of motoneurons immunoreactive for nitrotyrosine. Apoptotic motoneuron death, measured through annexin V-Cy3 and active caspase-3 immunoreactivities, was also found cooperatively induced by TNF-alpha and IFN-gamma. Interestingly, these cytokines did not affect the viability of purified spinal cord motoneurons in the absence of glial cells. It is proposed that the proinflammatory cytokines TNF-alpha and IFN-gamma have cooperative/complementary roles in inflammation-induced motoneuron death.
Collapse
Affiliation(s)
- M Mir
- Grup de Neurobiologia Cel.lular, Institut Universitari d'Investigacions en Ciències de la Salut/Departament de Biologia, Universitat de les Illes Balears, Cra. de Valldemossa, km 7.5, E-07122 Palma de Mallorca, Illes Balears, Spain
| | | | | | | | | | | | | |
Collapse
|
9
|
Tolosa L, Mir M, Olmos G, Lladó J. Vascular endothelial growth factor protects motoneurons from serum deprivation–induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition. Neuroscience 2009; 158:1348-55. [DOI: 10.1016/j.neuroscience.2008.10.060] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2008] [Revised: 10/17/2008] [Accepted: 10/31/2008] [Indexed: 11/30/2022]
|
10
|
Valiente O, Andueza D, de Vega A, Olmos G, Muñoz F. The use of NIRS for prediction of intake,
digestibility and diet composition in sheep fed
mixed grain:roughage diets. J Anim Feed Sci 2004. [DOI: 10.22358/jafs/73846/2004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Iglesias M, Segura MF, Comella JX, Olmos G. Mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase. Neuropharmacology 2003; 44:482-92. [PMID: 12646285 DOI: 10.1016/s0028-3908(03)00024-8] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Opioid peptides and alkaloids exert their effects via G protein-coupled receptors (GPCRs). It has been shown that, in addition to trophic factors, some GPCRs are able to activate the phosphatidylinositol 3-kinase/Akt (PI 3-K/Akt) signal transduction pathway, thus leading to cell survival. The aim of this study was to test whether activation of mu-opioid receptors has protective effects on serum withdrawal-induced cell death and to study the possible implication of PI 3-K in this process. In SH-SY5Y neuroblastoma cells fully differentiated by exposure to retinoic acid for five days, the enkephalin derivative selective mu-agonist DAMGO (0.1-2 microM) and the alkaloid morphine (0.1-10 microM) promoted cell survival after serum deprivation (MTT and trypan blue exclusion assays), without inducing cell proliferation. These effects were fully reversed by naloxone, by the selective mu-antagonist beta-funaltrexamine (beta-FNA) and also by the specific PI 3-K inhibitor LY294002. The two agonists stimulated Akt phosphorylation and the effect was also abolished by beta-FNA and by LY294002. In mouse primary cortical neurons, DAMGO reduced the percentage of apoptosis after 6, 12, 24 and 48 h of serum withdrawal; as determined by Hoechst staining. This effect was blocked by beta-FNA, by pre-treatment with pertussis toxin and by LY294002. DAMGO also stimulated Akt phosphorylation via PI 3-K in this primary neuronal culture. Together, these results indicate that stimulation of the mu-opioid receptor promotes neuronal survival in a G(i/o)-linked, PI 3-K-dependent signaling cascade and suggest that Akt may be a key downstream kinase involved in this anti-apoptotic effect.
Collapse
Affiliation(s)
- M Iglesias
- Grup de Neurobiologia Molecular, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Lleida, Spain
| | | | | | | |
Collapse
|
12
|
Lotero LA, Jordán JA, Olmos G, Alvarez FJ, Tejedor MC, Diez JC. Differential in vitro and in vivo behavior of mouse ascorbate/Fe3+ and diamide oxidized erythrocytes. Biosci Rep 2001; 21:857-71. [PMID: 12166832 DOI: 10.1023/a:1015545010121] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Chemical oxidation of mouse erythrocytes has been carried out using two different oxidizing systems namely: Diamide and Ascorbate/Fe3+ together with different concentrations of the oxidant. These oxidation treatments produced different extents of modification in membrane proteins as was observed by electrophoretic analyses that showed a possible formation of high molecular weight aggregates. Lipid peroxidation was also observed as the result of these chemical treatments. The action of these two oxidation treatments produced different extents of lipid peroxidation in which the effect Ascorbate/Fe3+ reached higher values than that shown by diamide treatments. To study the resulting in vitro behavior of such oxidized erythrocytes, we have evaluated the recognition of oxidized erythrocytes by peritoneal macrophages. In the conditions used, diamide oxidized erythrocytes were more highly recognized by macrophages than Ascorbate/Fe3+ treated erythrocytes. However, in both cases an influence of serum factors in the recognition process can be inferred. Additionally, we have correlated on one side the action of different oxidation systems on mouse erythrocytes with different in vivo behavior and organ uptake of the oxidized erythrocytes. On the other side, differential targeting of oxidized erythrocytes to a liver or spleen was observed on dependence of the oxidant used.
Collapse
Affiliation(s)
- L A Lotero
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Mouse carrier erythrocytes containing 125I-interleukin 3 have been prepared and treated with band 3 crosslinking reagents. The incorporation of interleukin 3 by hypotonic treatment into mouse erythrocytes reached levels of about 15% of the interleukin 3 added to the medium being predominantly present in the cytosolic fraction (73%). Uptake fell to about 7.4% when using the same conditions but omitting hypotonic shock. The interaction of band 3 crosslinked interleukin 3 loaded erythrocytes with macrophages was also studied. A high level of incorporation of interleukin 3 into macrophages was observed either from band 3 crosslinked, interleukin 3-loaded erythrocytes or from interleukin 3 loaded erythrocytes. The observations encourage the view that the system may be able to deliver and target cytokines and other growth factors to macrophages.
Collapse
Affiliation(s)
- G Olmos
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Madrid, Spain
| | | | | | | |
Collapse
|
14
|
Casanovas A, Olmos G, Ribera J, Boronat MA, Esquerda JE, García-Sevilla JA. Induction of reactive astrocytosis and prevention of motoneuron cell death by the I(2)-imidazoline receptor ligand LSL 60101. Br J Pharmacol 2000; 130:1767-76. [PMID: 10952664 PMCID: PMC1572252 DOI: 10.1038/sj.bjp.0703485] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2000] [Revised: 03/29/2000] [Accepted: 05/16/2000] [Indexed: 11/08/2022] Open
Abstract
I(2)-imidazoline receptors are mainly expressed on glial cells in the rat brain. This study was designed to test the effect of treatment with the I(2)-imidazoline selective receptor ligand LSL 60101 [2-(2-benzofuranyl)imidazole] on the morphology of astrocytes in the neonate and adult rat brain, and to explore the putative neuroprotective effects of this glial response. Short-term (3 days) or chronic (7-10 days) treatment with LSL 60101 (1 mg kg(-1), i.p. every 12 h) enhanced the area covered by astroglial cells in sections of facial motor nucleus from neonate rats processed for glial fibrillary acidic protein (GFAP) immunostaining. Facial motoneurons surrounded by positive glial cell processes were frequently observed in sections of LSL 60101-treated rats. A similar glial response was observed in the parietal cortex of adult rats after chronic (10 days) treatment with LSL 60101 (10 mg kg(-1), i.p. every 12 h). Western-blot detection of the specific astroglial glutamate transporter GLT-1, indicated increased immunoreactivity after LSL 60101 treatment in the pons of neonate and in the parietoccipital cortex of adult rats. In the facial motor nucleus of neonate rats, the glial response after LSL 60101 treatment was associated to a redistribution of the immunofluorescence of the basic fibroblast growth factor (FGF-2) from the perinuclear area of motoneurons to cover most of their cytoplasm, suggesting a translocation of this mitogenic and neurotrophic factor towards secretion pathways. The neuroprotective potential of the above effects of LSL 60101 treatment was tested after neonatal axotomy of facial motor nucleus. Treatment with LSL 60101 (1 mg kg(-1), i.p. every 12 h from day 0 to day 10 after birth) significantly reduced (38%) motoneuron death rate 7 days after facial nerve axotomy performed on day 3 after birth. It is concluded that treatment with the I(2)-imidazoline selective receptor ligand LSL 60101 provokes morphological/biochemical changes in astroglia that are neuroprotective after neonatal axotomy.
Collapse
Affiliation(s)
- A Casanovas
- Departament de Ciències Mèdiques Bàsiques, Unitat de Neurobiologia Cel.lular, Universitat de Lleida, Rovira Roure 44, E-25198 Lleida, Spain
| | | | | | | | | | | |
Collapse
|
15
|
Olmos G, Lotero LA, Herráez A, Alvarez FJ, Murciano JC, Tejedor MC, Díez JC. Influence of aerobic oxidation of mouse erythrocytes on their recognition by macrophages. Biosci Rep 2000; 20:157-66. [PMID: 11095115 DOI: 10.1023/a:1005511402046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Membrane protein modification can change cell surface properties which can be correlated with altered macrophage-erythrocyte interactions. Mouse erythrocytes were incubated in phosphate buffer for different times to induce protein modification. Mouse erythrocyte membrane changes were analyzed by infrared analyses and gel electrophoresis. Proteolytic digestion of membrane proteins was observed. After 22 hours preliminary incubation, the number of erythrocytes adhering to a monolayer of macrophages reached a maximum, the majority of which had not been phagocytosed. Most of the erythrocytes incubated for 40 hours underwent phagocytosis after adhesion to the macrophages.
Collapse
Affiliation(s)
- G Olmos
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
16
|
Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpció Boronat M, Trullas R, Villarroel A, Lerma J, García-Sevilla JA. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 1999; 127:1317-26. [PMID: 10455281 PMCID: PMC1760666 DOI: 10.1038/sj.bjp.0702679] [Citation(s) in RCA: 136] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
This study was designed to assess the potential neuroprotective effect of several imidazol(ine) drugs and agmatine on glutamate-induced necrosis and on apoptosis induced by low extracellular K+ in cultured cerebellar granule cells. Exposure (30 min) of energy deprived cells to L-glutamate (1-100 microM) caused a concentration-dependent neurotoxicity, as determined 24 h later by a decrease in the ability of the cells to metabolize 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) into a reduced formazan product. L-glutamate-induced neurotoxicity (EC50=5 microM) was blocked by the specific NMDA receptor antagonist MK-801 (dizocilpine). Imidazol(ine) drugs and agmatine fully prevented neurotoxicity induced by 20 microM (EC100) L-glutamate with the rank order (EC50 in microM): antazoline (13)>cirazoline (44)>LSL 61122 [2-styryl-2-imidazoline] (54)>LSL 60101 [2-(2-benzofuranyl) imidazole] (75)>idazoxan (90)>LSL 60129 [2-(1,4-benzodioxan-6-yl)-4,5-dihydroimidazole](101)>RX82 1002 (2-methoxy idazoxan) (106)>agmatine (196). No neuroprotective effect of these drugs was observed in a model of apoptotic neuronal cell death (reduction of extracellular K+) which does not involve stimulation of NMDA receptors. Imidazol(ine) drugs and agmatine fully inhibited [3H]-(+)-MK-801 binding to the phencyclidine site of NMDA receptors in rat brain. The profile of drug potency protecting against L-glutamate neurotoxicity correlated well (r=0.90) with the potency of the same compounds competing against [3H]-(+)-MK-801 binding. In HEK-293 cells transfected to express the NR1-1a and NR2C subunits of the NMDA receptor, antazoline and agmatine produced a voltage- and concentration-dependent block of glutamate-induced currents. Analysis of the voltage dependence of the block was consistent with the presence of a binding site for antazoline located within the NMDA channel pore with an IC50 of 10-12 microM at 0 mV. It is concluded that imidazol(ine) drugs and agmatine are neuroprotective against glutamate-induced necrotic neuronal cell death in vitro and that this effect is mediated through NMDA receptor blockade by interacting with a site located within the NMDA channel pore.
Collapse
Affiliation(s)
- G Olmos
- Associate Unit of the Institute Cajal/Consejo Superior de Investigaciones Científicas, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
I2-imidazoline receptors (I2-IR) are characterized by their high affinity for imidazolines and guanidines and medium affinity for imidazolidines. The differential recognition of I2-IR by amiloride led to subtype these sites as amiloride-sensitive (I2A-IR) and amiloride-insensitive (I2B-IR). I2-IR labeled with [3H]idazoxan or [3H]2-BFI in the rabbit cerebral cortex (I2A-IR) displayed higher affinities for amiloride and amiloride analogs than in the rat cerebral cortex (I2B-IR). Other drugs tested displayed biphasic curves in competition experiments, indicating the existence of high and low affinity sites for both I2-IR subtypes. The drugs (+)- and (-)-medetomidine, bromoxidine, moxonidine, and clorgyline were more potent on the high and/or low affinity sites of I2B-IR than on I2A-IR. Preincubation (30 min at 25 degrees C) with 10(-6) M isothiocyanatobenzyl imidazoline (IBI) or with 10(-6) M clorgyline reduced by 40% and 26%, respectively, the binding of [3H]2-BFI to I2B-IR, but it did not alter the binding of the radioligand to I2A-IR. These results indicated that the I2-IR subtypes differ in their pharmacologic profiles and in the nature of the imidazoline binding site involved in clorgyline and IBI alkylation. In rat cortical membranes, western blot detection of immunoreactive imidazoline receptor proteins revealed a double band of approximately 29/30 kD and three less intense bands of approximately 45, approximately 66, and approximately 85 kD. In rabbit cortical membranes the antibody detected proteins of approximately 30, approximately 57, approximately 66, and approximately 85 kD. It is suggested that I2-IR may be related to more than one receptor protein and that I2-IR subtypes differ in the nature of the proteins implicated.
Collapse
Affiliation(s)
- G Olmos
- Institute of Neurobiology Ramón y Cajal, CSIC, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
18
|
DeGregorio-Rocasolano N, Olmos G, Gasull T, Boronat MA, Trullas R, García-Sevilla JA. Protection by imidazol(ine) compounds of L-glutamate neurotoxicity through NMDA receptor blockade. Ann N Y Acad Sci 1999; 881:452. [PMID: 10415949 DOI: 10.1111/j.1749-6632.1999.tb09393.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Affiliation(s)
- M A Boronat
- Institute of Neurobiology Ramón y Cajal/CSIC, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
20
|
Boronat MA, Olmos G, García-Sevilla JA. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Br J Pharmacol 1998; 125:175-85. [PMID: 9776358 PMCID: PMC1565592 DOI: 10.1038/sj.bjp.0702031] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
1. Agmatine, the proposed endogenous ligand for imidazoline receptors, has been shown to attenuate tolerance to morphine-induced antinociception (Kolesnikov el al., 1996). The main aim of this study was to assess if idazoxan, an alpha2-adrenoceptor antagonist that also interacts with imidazoline receptors, could also modulate opioid tolerance in rats and to establish which type of imidazoline receptors (or other receptors) are involved. 2. Antinociceptive responses to opioid drugs were determined by the tail-flick test. The acute administration of morphine (10 mg kg(-1), i.p., 30 min) or pentazocine (10 mg kg(-1), i.p., 30 min) resulted in marked increases in tail-flick latencies (TFLs). As expected, the initial antinociceptive response to the opiates was lost after chronic (13 days) treatment (tolerance). When idazoxan (10 mg kg(-1), i.p.) was given chronically 30 min before the opiates it completely prevented morphine tolerance and markedly attenuated tolerance to pentazocine (TFLs increased by 71-143% at day 13). Idazoxan alone did not modify TFLs. 3. The concurrent chronic administration (10 mg kg(-1), i.p., 13 days) of 2-BFI, LSL 60101, and LSL 61122 (valldemossine), selective and potent I2-imidazoline receptor ligands, and morphine (10 mg kg(-1), i.p.), also prevented or attenuated morphine tolerance (TFLs increased by 64 172% at day 13). This attenuation of morphine tolerance was still apparent six days after discontinuation of the chronic treatment with LSL 60101-morphine. The acute treatment with these drugs did not potentiate morphine-induced antinociception. These drugs alone did not modify TFLs. Together, these results indicated the specific involvement of I2-imidazoline receptors in the modulation of opioid tolerance. 4. The concurrent chronic (13 days) administration of RX821002 (10 mg kg(-1), i.p.) and RS-15385-197 (1 mg kg(-1), i.p.), selective alpha2-adrenoceptor antagonists, and morphine (10 mg kg(-1), i.p.), did not attenuate morphine tolerance. Similarly, the concurrent chronic treatment of moxonidine (1 mg kg(-1), i.p.), a mixed I(1)-imidazoline receptor and alpha2-adrenoceptor agonist, and morphine (10 mg kg(-1), i.p.), did not alter the development of tolerance to the opiate. These results discounted the involvement of alpha2-adrenoceptors and I(1)-imidazoline receptors in the modulatory effect of idazoxan on opioid tolerance. 5. Idazoxan and other imidazol(ine) drugs fully inhibited [3H]-(+)-MK-801 binding to N-methyl-D-aspartate (NMDA) receptors in the rat cerebral cortex with low potencies (Ki: 37-190 microM). The potencies of the imidazolines idazoxan, RX821002 and moxonidine were similar, indicating a lack of relationship between potency on NMDA receptors and ability to attenuate opioid tolerance. These results suggested that modulation of opioid tolerance by idazoxan is not related to NMDA receptors blockade. 6. Chronic treatment (13 days) with morphine (10 mg kg(-1), i.p.) was associated with a marked decrease (49%) in immunolabelled neurofilament proteins (NF-L) in the frontal cortex of morphine-tolerant rats, suggesting the induction of neuronal damage. Chronic treatment (13 days) with idazoxan (10 mg kg(-1)) and LSL 60101 (10 mg kg(-1)) did not modify the levels of NF-L proteins in brain. Interestingly, the concurrent chronic treatment (13 days) of idazoxan or LSL 60101 and morphine, completely reversed the morphine-induced decrease in NF-L immunoreactivity, suggesting a neuroprotective role for these drugs. 7. Together, the results indicate that chronic treatment with I2-imidazoline ligands attenuates the development of tolerance to opiate drugs and may induce neuroprotective effects on chronic opiate treatment. Moreover, these findings offer the I2-imidazoline ligands as promising therapeutic coadjuvants in the management of chronic pain with opiate drugs.
Collapse
Affiliation(s)
- M A Boronat
- Institute Cajal/CSIC, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
21
|
Alvarez FJ, Jordán JA, Calleja P, Lotero LA, Olmos G, Díez JC, Tejedor MC. Cross-linking treatment of loaded erythrocytes increases delivery of encapsulated substance to macrophages. Biotechnol Appl Biochem 1998; 27:139-43. [PMID: 9569609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Previous investigation has shown that osmotically loaded erythrocytes can act as drug carriers in systemic circulation, whereas chemically modified erythrocytes can be targeted to organs of the mononuclear phagocytic system because of changes introduced in the membrane that are recognized by macrophage cells. In this study we have examined the delivery of 125I-labelled carbonic anhydrase (125I-CA) carried by mouse erythrocytes, either loaded, or loaded and cross-linked with bis(sulphosuccinimidyl)suberate (BS3) and 3,3'-dithiobis-(sulphosuccinimidyl propionate), into homologous peritoneal macrophages maintained in culture. The hypotonically loaded mouse erythrocytes show a slight recognition by macrophages, similar to native erythrocytes. CA loaded into erythrocytes is thus delivered to a limited extent into macrophages. Neither the number of recognized loaded 51Cr-labelled erythrocytes nor the amount of delivered 125I-CA is affected by the presence of serum components or IgG. In contrast, cross-linking these loaded erythrocytes results in a greater phagocytosis by macrophages as assessed by microscopic observations, producing a markedly increased amount of targeted enzyme. The amount of CA delivered into macrophages, after BS3 cross-linker treatment of erythrocytes, is dependent on the presence of serum components in the incubation medium. Thus these cross-linking treatments improve the capacity of loaded mouse erythrocytes to deliver significant amounts of targeted enzyme to macrophage cells, increasing the therapeutic potential of carrier erythrocytes.
Collapse
Affiliation(s)
- F J Alvarez
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
22
|
Jordán JA, Alvarez FJ, Lotero LA, Olmos G, Calleja P, Tejedor MC, Díez JC. Differential induction of macrophage recognition of carrier erythrocytes by treatment with band 3 cross-linkers. Biotechnol Appl Biochem 1998; 27:133-7. [PMID: 9569608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Mouse native and hypotonically loaded erythrocytes were treated with two cross-linking reagents: bis(sulphosuccinimidyl)suberate (BS3)- and 3,3'-dithiobis-(sulphosuccinimidyl propionate) (DTSP), excluding clustering agents. Microscopic analyses revealed that band 3 cross-linked native and hypotonically loaded erythrocytes are more strongly recognized by peritoneal macrophages than native and loaded erythrocytes as a result of the cross-linking of band 3 protein in accordance with studies in vivo. Macrophage-recognition analyses of 51Cr-labelled erythrocytes also demonstrated increased recognition of cross-linked and cross-linked loaded erythrocytes. This shows that the only action of these two band 3 cross-linkers on mouse erythrocytes promotes recognition by macrophages without requiring the use of clustering agents. The extent of recognition of BS3 cross-linked and cross-linked loaded erythrocytes by macrophages is dependent on the presence or absence of homologous serum or immunoglobulins. In contrast, the presence of serum factors or IgG in the incubation medium did not seem to influence the recognition of DTSP-modified erythrocytes by macrophages. These results seem to indicate a different mechanism of recognition for the erythrocytes modified with either one or the other band 3 cross-linker. In summary, the unique use of both band 3 cross-linkers procedures can be used to target carrier erythrocytes conveying active compounds to macrophages, with possible therapeutical applications. Different mechanisms of induction of macrophage recognition by these band 3 cross-linkers could reveal differential actions on erythrocytes or the involvement of different factors in the recognition process.
Collapse
Affiliation(s)
- J A Jordán
- Departamento de Bioquímica y Biología Molecular, Campus Universitario, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
23
|
Boronat MA, Olmos G, Miller DD, Patil PN, García-Sevilla JA. Isothiocyanatobenzyl imidazoline is an alkylating agent for I2-imidazoline binding sites in rat and rabbit tissues. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:351-5. [PMID: 9550309 DOI: 10.1007/pl00005178] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Isothiocyanatobenzyl imidazoline (IBI), the 4'-NCS analogue of tolazoline, has been used to alkylate several receptor sites in rabbit iris muscles. Because of the high affinity of tolazoline for the I2-imidazoline binding sites (Ki = 16-130 nM), this study was designed to assess whether IBI is also an alkylating agent for these sites. In competition studies, IBI displayed moderate affinity (Ki approximately 2-3 microM) against I2A-imidazoline sites in the rabbit cerebral cortex and I2B-imidazoline sites in the rat cerebral cortex labelled by [3H]2-(2-benzofuranyl)-2-imidazoline ([3H]2-BFI). However, preincubation (30 min at 25 degrees C) of rat cortical and liver membranes with IBI (10(-7) M to 10(-3) M), followed by extensive washing, markedly decreased (17% to 96%) the specific binding of [3H]2-BFI to I2B-imidazoline sites. IBI (10(-5) M to 10(-3) M) also bound irreversibly to I2A-imidazoline sites in rabbit cerebral cortex but with a lesser efficacy (27% to 83% reduction of [3H]2-BFI binding). Saturation curves of [3H]2-BFI binding in the rat cerebral cortex indicated that preincubation with 10(-6) M IBI reduced the total density (Bmax) without affecting the affinity (Kd) of I2B-imidazoline sites for IBI. Acute treatments (6 h) with IBI (10 and 30 mg/kg, i.p.) also dose-dependently reduced (26% and 41%; respectively) the total density of I2B-imidazoline sites. These results demonstrate the ability of IBI to alkylate I2-imidazoline binding sites in vitro and in vivo and provide evidence for the use of IBI as a new tool for the study of the functional implications of imidazoline binding sites.
Collapse
Affiliation(s)
- M A Boronat
- Institute of Neurobiology Ramón y Cajal, CSIC, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | |
Collapse
|
24
|
Ozaita A, Olmos G, Boronat MA, Lizcano JM, Unzeta M, García-Sevilla JA. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br J Pharmacol 1997; 121:901-12. [PMID: 9222546 PMCID: PMC1564771 DOI: 10.1038/sj.bjp.0701214] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
1. I2-Imidazoline sites ([3H]-idazoxan binding) have been identified on monoamine oxidase (MAO) and proposed to modulate the activity of the enzyme through an allosteric inhibitory mechanism (Tesson et al., 1995). The main aim of this study was to assess the inhibitory effects and nature of the inhibition of imidazol(ine)/guanidine drugs on rat liver MAO-A and MAO-B isoforms and to compare their inhibitory potencies with their affinities for the sites labelled by [3H]-clonidine in the same tissue. 2. Competition for [3H]-clonidine binding in rat liver mitochondrial fractions by imidazol(ine)/guanidine compounds revealed that the pharmacological profile of the interaction (2-styryl-2-imidazoline, LSL 61112 > idazoxan > 2-benzofuranyl-2-imidazoline, 2-BFI = cirazoline > guanabenz > oxymetazoline > > clonidine) was typical of that for I2-sites. 3. Clonidine inhibited rat liver MAO-A and MAO-B activities with very low potency (IC50S: 700 microM and 6 mM, respectively) and displayed the typical pattern of competitive enzyme inhibition (lineweaver-Burk plots: increased K(m) and unchanged Vmax values). Other imidazol(ine)/guanidine drugs also were weak MAO inhibitors with the exception of guanabenz, 2-BFI and cirazoline on MAO-A (IC50S: 4-11 microM) and 2-benzofuranyl-2-imidazol (LSL 60101) on MAO-B (IC50: 16 microM). Idazoxan was a full inhibitor although with rather low potency, on both MAO-A and MAO-B isoenzymes (IC50S: 280 microM and 624 microM, respectively). Kinetic analyses of MAO-A inhibition by these drugs revealed that the interactions were competitive. For the same drugs acting on MAO-B the interactions were of the mixed type inhibition (increased K(m) and decreased Vmax values), although the greater inhibitory effects on the apparent value of Vmax/K(m) than on the Vmax value indicated that the competitive element of the MAO-B inhibition predominated. 4. Competition for [3H]-Ro 41-1049 binding to MAO-A or [3H]-Ro 19-6327 binding to MAO-B in rat liver mitochondrial fractions by imidazol(ine)/guanidine compounds revealed that the drug inhibition constants (Ki values) were similar to the IC50 values displayed for the inhibition of MAO-A or MAO-B activities In fact, very good correlations were obtained when the affinities of drugs at MAO-A or MAO-B catalytic sites were correlated with their potencies in inhibiting MAO-A (r = 0.92) or MAO-B (r = 0.99) activity. This further suggested a direct drug interaction with the catalytic sites of MAO-A and MAO-B isoforms. 5. No significant correlations were found when the potencies of imidazol(ine)/guanidine drugs at the high affinity site (pKiH, nanomolar range) or the low-affinity site (pKiL, micromolar range) of I2-imidazoline receptors labelled with [3H]-clonidine were correlated with the pIC50 values of the same drugs for inhibition of MAO-A or MAO-B activity. These discrepancies indicated that I2-imidazoline receptors are not directly related to the site of action of these drugs on MAO activity in rat liver mitochondrial fractions. 6. Although these studies cannot exclude the presence of additional binding sites on MAO that do not affect the activity of the enzyme, they would suggest that I2-imidazoline receptors represent molecular species that are distinct from MAO.
Collapse
Affiliation(s)
- A Ozaita
- Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | |
Collapse
|
25
|
Alemany R, Olmos G, García-Sevilla JA. Labelling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn Schmiedebergs Arch Pharmacol 1997; 356:39-47. [PMID: 9228188 DOI: 10.1007/pl00005026] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The novel selective imidazoline radioligand [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) was used to characterize and assess further the nature of I2-imidazoline receptors in rat brain and liver. In the cerebral cortex, 2-BFI displayed high affinity (Ki = 9.8 nM) for a single class of [3H]2-BFI binding sites. Other imidazoline/guanidine compounds (e.g. aganodine, cirazoline and idazoxan) displayed biphasic competition curves, indicating the existence of high (KiH = 2.9-78 nM; R(H) = 61-83%) and low (KiL = 4.7-158 microM) affinity sites. The pharmacological profile for [3H]2-BFI binding (aganodine > cirazoline > 2-BFI >> clonidine > amiloride >> efaroxan) was typical of that for I2-sites. This profile was almost identical to that obtained against [3H]idazoxan (correlation between pKi values, r = 0.97) which indicated that the sites characterized with [3H]2-BFI in brain corresponded to I2-imidazoline receptors. The low affinity of amiloride against [3H]2-BFI (Ki = 900 nM) further indicated that these brain I2-sites belong to the I2B-subtype. [3H]2-BFI binding sites (Bmax = 72 fmol/mg protein) in brain were differentially modulated by treatment (7 days) with cirazoline (up-regulation: 25%) and the MAO inhibitor phenelzine (down-regulation: 31%), indicating that these I2-sites are regulated in vivo, as is the case for those labelled by [3H]idazoxan. Chronic treatment with 2-phenylethylamine, a phenelzine metabolite and endogenous amine, did not alter the density of brain of I2-imidazoline receptors labelled by [3H]idazoxan. Preincubation of liver membranes with the MAO inhibitor clorgyline (10(-7) M) abolished the binding of [3H]Ro 41-1049 (N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide) to MAO-A, but it did not alter the binding of [3H]Ro 19-6327 (N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide) to MAO-B or that of [3H]2-BFI to I2-sites. At 10(-4) M it also abolished MAO-B sites, but a substantial proportion of I2-sites (40%) remained intact. Preincubation of liver membranes at 60 degrees C also abolished MAO-A/B sites, whereas still 22% of I2-sites remained. The results indicate that [3H]2-BFI is a good tool for the identification of I2-imidazoline receptors and suggest further that certain I2-sites and MAO are different proteins.
Collapse
Affiliation(s)
- R Alemany
- Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
26
|
Olmos G, Alemany R, García-Sevilla JA. Pharmacological and molecular discrimination of brain I2-imidazoline receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 1996; 354:709-16. [PMID: 8971730 DOI: 10.1007/bf00166896] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
I2-imidazoline receptors labelled with [3H]-idazoxan in the rabbit and rat brains displayed high and low affinity, respectively, for the guanidide amiloride; reinforcing the previous definition of I2A-imidazoline receptors expressed in the rabbit brain and I2B-imidazoline receptors expressed in the rat brain. Other drugs tested displayed biphasic curves in competition experiments, indicating the existence of high and low affinity sites for both subtypes of I2-imidazoline receptors. Among the drugs studied, bromoxidine, moxonidine, (+)- and (-)-medetomidine and clorgyline were more potent on the high and/or low affinity sites of I2B-than on their corresponding of I2A-imidazoline receptors (KiH ratios 20 to 65). No correlation was found for the potencies of the drugs tested at the low affinity sites of both I2-imidazoline receptor subtypes. Preincubation (30 min at 25 degrees C) with 10(-6) M clorgyline reduced by 60% the Bmax of [3H]-idazoxan binding to I2B-imidazoline receptors in the rat brain, but it did not affect the binding parameters of the radioligand saturation curves to I2A-imidazoline receptors in the rabbit brain. These results indicated that I2A- and I2B-imidazoline receptor subtypes differ in the pharmacological profiles of their high and low affinity sites and in the ability to irreversibly bind clorgyline. In rat cortical membranes western blot detection of immunoreactive imidazoline receptors proteins revealed a double band of approximately 29/30 kDa and two less intense bands of approximately 45 and approximately 66 kDa. In rabbit cortical membranes the antibody used detected proteins of approximately 30, approximately 57 and approximately 66 kDa. It is suggested that different imidazoline receptor proteins (approximately 45 vs approximately 57 kDa) may account for the different pharmacological profiles of I2-imidazoline receptor subtypes.
Collapse
Affiliation(s)
- G Olmos
- Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
27
|
Abstract
The effects of several imidazoli(di)ne compounds on the binding of the non-competitive NMDA receptor antagonist [3H](+)-MK-801 (dizocilpine) to rat brain membranes were studied. These compounds fully inhibit radioligand binding with potencies in the micromolar range. The obtained profile of drug affinity correlated well with the potency of the same compounds promoting insulin release by blocking ATP-sensitive K+ channels in the rat insulinoma cell line RIN-5AH. It is suggested that imidazoli(di)ne compounds interact with cation channels sharing a common phencyclidine binding site (e.g. NMDA receptors, K+ channels and nicotinic acetylcholine receptors) and that this could be the basis of some biological effects of imidazoli(di)nes.
Collapse
Affiliation(s)
- G Olmos
- Departament de Biologia, Universitat de les Illes Balears, Balears, Spain
| | | | | |
Collapse
|
28
|
Escribá PV, Alemany R, Sastre M, Olmos G, Ozaita A, García-Sevilla JA. Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non-adrenoceptor [3H]-idazoxan binding sites. Br J Pharmacol 1996; 118:2029-36. [PMID: 8864539 PMCID: PMC1909863 DOI: 10.1111/j.1476-5381.1996.tb15640.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
1. The densities of various imidazoline receptor proteins (with apparent molecular masses of approximately 29/30-45- and 66-kDa) were quantitated by immunoblotting in the rat cerebral cortex after various drug treatments. The modulation of these imidazoline receptor proteins was then compared with the changes in the density of non-adrenoceptor [3H]-idazoxan binding sites (I2-sites) induced by the same drug treatments. 2. Chronic treatment (7 days) with the I2-selective imidazol(in)e drugs idazoxan (10 mg kg-1), cirazoline (1 mg kg-1) and LSL 60101 (10 mg kg-1) differentially increased the immunoreactivity of imidazoline receptor proteins. The levels of the 29/30-kDa protein were increased by idazoxan and LSL 60101 (23%), the levels of the 45-kDa protein only by cirazoline (44%) and those of the 66-kDa protein only by idazoxan (50%). These drug treatments also increased the density of I2-sites (32-42%). 3. Chronic treatment (7 days) with efaroxan (10 mg kg-1), RX821002 (10 mg kg-1) and yohimbine (10 mg kg-1), which possess very low affinity for I2-imidazoline receptors, did not alter either the immunoreactivity of imidazoline receptor proteins or the density of I2-sites. 4. Chronic treatment (7 days) with the monoamine oxidase (MAO) inhibitors clorgyline (10 mg kg-1) and phenelzine (10 mg kg-1) decreased the immunoreactivity of the 29/30-kDa (17-24%), 45-kDa (19%) and 66-kDa (23-31%) imidazoline receptor proteins. The alkylating agent N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (1.6 mg kg-1, 6 h) also decreased the levels of the three imidazoline receptor proteins (20-47%). These drug treatments consistently decreased the density of I2-sites (31-57%). 5. Significant correlations were found when the mean percentage changes in immunoreactivity of imidazoline receptor proteins were related to the mean percentage changes in the density of I2-sites after the various drug treatments (r = 0.92 for the 29/30-kDa protein, r = 0.69 for the 45-kDa protein and r = 0.75 for the 66-kDa protein). 6. In the rat cerebral cortex the I2-imidazoline receptor labelled by [3H]-idazoxan is heterogeneous in nature and the related imidazoline receptor proteins (29/30-, 45- and 66-kDa) detected by immunoblotting contribute differentially to the modulation of I2-sites after drug treatment.
Collapse
Affiliation(s)
- P V Escribá
- Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | |
Collapse
|
29
|
García-Sevilla JA, Alemany R, Olmos G, Menargues A, Obach R. Chronic imidazoline drug treatment increases the immunoreactivity of glial fibrillary acidic protein in rat brain. LSL 60101 as a novel and selective ligand for I2-imidazoline receptors. Ann N Y Acad Sci 1995; 763:486-9. [PMID: 7677361 DOI: 10.1111/j.1749-6632.1995.tb32437.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- J A García-Sevilla
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | |
Collapse
|
30
|
Affiliation(s)
- J García-Sevilla
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | |
Collapse
|
31
|
Olmos G, Kulkarni RN, Haque M, MacDermot J. Imidazolines stimulate release of insulin from RIN-5AH cells independently from I1- and I2-imidazoline receptors. Ann N Y Acad Sci 1995; 763:374-6. [PMID: 7677349 DOI: 10.1111/j.1749-6632.1995.tb32425.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- G Olmos
- Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, UK
| | | | | | | |
Collapse
|
32
|
Alemany R, Olmos G, García-Sevilla JA. Chronic treatment with phenelzine and other irreversible monoamine oxidase inhibitors downregulates I2-imidazoline receptors in the brain and liver. Ann N Y Acad Sci 1995; 763:506-9. [PMID: 7677366 DOI: 10.1111/j.1749-6632.1995.tb32442.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- R Alemany
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
33
|
Alemany R, Olmos G, Escribá PV, Menargues A, Obach R, García-Sevilla JA. LSL 60101, a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration. Eur J Pharmacol 1995; 280:205-10. [PMID: 7589187 DOI: 10.1016/0014-2999(95)00214-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The concentration of the astrocytic marker, glial fibrillary acidic protein (GFAP) was quantitated by immunoblotting (Western blotting) in the rat brain after treatment with the novel ligand for imidazoline I2 receptors LSL 60101 [2-(2-benzofuranyl)imidazole] and its 6-methoxy derivative LSL 60125. Chronic (7-21 days), but not acute (1 day) or short-term (3 days), treatment with LSL 60101 (10 mg/kg i.p.) markedly increased (44-49%) GFAP immunoreactivity in the rat cerebral cortex. In contrast, chronic (7 days) treatment with LSL 60125 (10 mg/kg i.p.) did not significantly modify GFAP concentrations. In vitro, both drugs displayed moderate high affinity and high selectivity for imidazoline I2 receptors versus alpha 2-adrenoceptors; however, only chronic treatment with LSL 60101 (10 mg/kg i.p.) but not with LSL 60125 (10 mg/kg i.p.) was associated with an up-regulation of imidazoline I2 receptors. These data indicate that glial imidazoline I2 receptors may have a direct physiological function related to GFAP expression and that LSL 60101 could be a good tool for the study of the implication of these receptors on astrocyte activation and neuronal regeneration.
Collapse
Affiliation(s)
- R Alemany
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | |
Collapse
|
34
|
Alemany R, Olmos G, García-Sevilla JA. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors. Br J Pharmacol 1995; 114:837-45. [PMID: 7773544 PMCID: PMC1510217 DOI: 10.1111/j.1476-5381.1995.tb13280.x] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
1. The binding of [3H]-idazoxan in the presence of 10(-6) M (-)-adrenaline was used to quantitate I2 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irreversible and reversible monoamine oxidase (MAO) inhibitors. 2. Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-1, i.p.), isocarboxazid (10 mg kg-1, i.p.), clorgyline (3 mg kg-1, i.p.) and tranylcypromine (10 mg kg-1, i.p.) markedly decreased (21-71%) the density of I2 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-1, i.p.) or chlordimeform (10 mg kg-1, i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-1, i.p.) did not alter the density of I2 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3. In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform displaced the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites. Phenelzine, 3-phenylpropargylamine and tranylcypromine displayed moderate affinity (KiH = 0.3-6 microM) for brain and liver I2 imidazoline-preferring receptors; whereas chlordimeform displayed high affinity (KiH = 6 nM) for these receptors in the two tissues studied, Clorgyline displayed very high affinity for rat brain (KiH = 40 pM) but not for rat liver I2 imidazoline-preferring receptors (KiH = 169 nM). 4. Preincubation of cortical or liver membranes with phenelzine (10-4 M for 30 min) did not alter the total density of I2 imidazoline-preferring receptors, indicating that this irreversible MAO inhibitor does not irreversibly bind to I2 imidazoline-preferring receptors. In contrast, preincubation with 10-6 Mclorgyline reduced by 40% the Bmax of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors.5. Chronic treatment (7 days) with the inducers of cytochrome P-450 enzymes phenobarbitone (40 or 80 mg kg-1, i.p.), 3-methylcholanthrene (20 mg kg-1, i.p.) or 2-methylimidazole (40 mg kg-1, i.p.) did not alter the binding parameters of [3H]-idazoxan to brain and liver 12 imidazoline-preferring receptors.The compound SKF 525A, a potent inhibitor of cytochrome P-450 enzymes which forms a tight but reversible complex with the haemoprotein, completely displaced with moderate affinity (KiH = 2-10 microM)the specific binding of [3H]-idazoxan to brain and liver 12 imidazoline-preferring receptors. Preincubation of total liver homogenates with 3 x 10-4 M phenelzine in the presence of 10-3 M NADH, a treatment that irreversibly inactivates the haeme group of cytochrome P-450, did not reduce the density of liver I2 imidazoline-preferring receptors. These results discounted a possible interaction of [3H]-idazoxan with the haeme group of cytochrome P-450 enzymes.6. Together the results indicate that the down-regulation of I2 imidazoline-preferring receptors is associated with an irreversible inactivation of MAO (at least in the brain) that is not related either to the affinity of the MAO inhibitors for I2 imidazoline-preferring receptors or to an irreversible binding to these putative receptors. These findings indicate a novel effect of irreversible MAO inhibitors in the brain and suggest a new target for these compounds that could be of relevance in the treatment of depression, a disease in which an increased density of brain I2 imidazoline-preferring receptors has been reported.
Collapse
Affiliation(s)
- R Alemany
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | |
Collapse
|
35
|
Donnelly LE, Boyd RS, Clifford CP, Olmos G, Allport JR, Lo G, MacDermot J. Endogenous substrates and functional role of eukaryotic mono(ADP-ribosyl) transferases. Biochem Pharmacol 1994; 48:1669-75. [PMID: 7980634 DOI: 10.1016/0006-2952(94)90450-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- L E Donnelly
- Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, U.K
| | | | | | | | | | | | | |
Collapse
|
36
|
Olmos G, Kulkarni RN, Haque M, MacDermot J. Imidazolines stimulate release of insulin from RIN-5AH cells independently from imidazoline I1 and I2 receptors. Eur J Pharmacol 1994; 262:41-8. [PMID: 7813577 DOI: 10.1016/0014-2999(94)90026-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The effect on insulin release of efaroxan, an alpha 2-adrenoceptor antagonist and a highly potent drug at imidazoline I1 receptors, and the effects of seven other imidazoline compounds selective for the imidazoline I1 or I2 receptors, were studied in the rat insulinoma cell line RIN-5AH. The cells released insulin in response to glucose (0.3-10 mM), and efaroxan (100 microM) potentiated glucose-induced insulin release. (-)-Adrenaline completely displaced the binding of [125I]p-iodoclonidine to membranes of RIN-5AH cells, indicating that these cells do not express imidazoline I1 receptors. Cirazoline and idazoxan (100 microM), both highly potent drugs at imidazoline I2 receptors, and the guanidines guanoxan and amiloride (200 microM), also promoted insulin release from RIN-5AH cells. Irreversible blockade of imidazoline I2 receptors with 10 microM clorgyline did not prevent the stimulatory effects of cirazoline or idazoxan; however, these compounds completely reversed the inhibition by diazoxide (250 microM), an opener of ATP-dependent K+ channels (K+ATP channels), of glucose-induced insulin release. These data indicate that the imidazoline/guanidine compounds promote insulin release from RIN-5AH cells, by interacting with a novel binding site related to K+ATP channels that does not represent any of the known imidazoline I1 or I2 receptors.
Collapse
Affiliation(s)
- G Olmos
- Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, UK
| | | | | | | |
Collapse
|
37
|
Olmos G, Alemany R, Escriba PV, García-Sevilla JA. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br J Pharmacol 1994; 111:997-1002. [PMID: 8032628 PMCID: PMC1910123 DOI: 10.1111/j.1476-5381.1994.tb14842.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
1. The concentration of the astrocytic marker, glial fibrillary acidic protein (GFAP) was quantitated by immunoblotting (western blotting) in the rat brain after treatment with various imidazoline drugs and other agents. 2. Chronic (7 days) but not acute (1 day) treatment with the imidazoline drugs, cirazoline (1 mg kg-1, i.p.) and idazoxan (10 mg kg-1, i.p.), but not with the structurally related alpha 2-adrenoceptor antagonists, RX821002 (2-methoxy idazoxan) (10 mg kg-1, i.p.) and efaroxan (10 mg kg-1, i.p.), markedly increased (45%) GFAP immunoreactivity in the rat cerebral cortex. Chronic treatment (7 days) with yohimbine (10 mg kg-1, i.p.), a non-imidazoline alpha 2-adrenoceptor antagonist, did not significantly modify GFAP immunoreactivity in the cerebral cortex. 3. Chronic treatment (7 days) with cirazoline and idazoxan did not alter the density of brain monoamine oxidase (MAO)-B sites labelled by [3H]-Ro 19-6327 (lazabemide), another relevant astroglial marker. Moreover, these imidazoline drug treatments did not modify the levels of alpha-tubulin in the cerebral cortex. These negative results reinforced the specificity of the effects of imidazoline drugs on GFAP. 4. Irreversible inactivation of brain alpha 2-adrenoceptors (and other neurotransmitters receptors) after treatment with an optimal dose of the peptide-coupling agent EEDQ (1.6 mg kg-1, i.p., for 6-24 h) did not alter GFAP immunoreactivity in the cerebral cortex. These results further disproved the involvement of these receptors on astroglial cells in the tonic control of GFAP levels.5. The binding of [3H]-idazoxan in the presence of 10-6 M (-)-adrenaline was used to quantitate in parallel 12-imidazoline preferring sites in the rat brain after the same treatments. Chronic treatment (7 days) with cirazoline and idazoxan, but not with RX821002, efaroxan or yohimbine, significantly increased (25%) the density of I2-sites in the cerebral cortex. The up-regulation of I2-sites induced by cirazoline was not observed in the liver, a tissue that also expresses 12-sites but lacks glial cells.6. A strong correlation (r = 0.97) was found when the mean percentage changes in GFAP immuno reactivity were related to the mean percentage changes in 12 imidazoline sites after the various drug treatments.7. Together the results suggest a direct physiological function of glial I2-imidazoline preferring sites in the regulation of GFAP levels.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
38
|
Miralles A, Ribas C, Olmos G, García-Sevilla JA. Differential effects of the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on brain alpha 2-adrenoceptors and I2-imidazoline sites in vitro and in vivo. J Neurochem 1993; 61:1602-10. [PMID: 8228980 DOI: 10.1111/j.1471-4159.1993.tb09793.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) is a peptide-coupling agent that is being used to inactivate irreversibly alpha 2-adrenoceptors and other receptors. The aim of the present study was to assess the in vitro and in vivo effects of EEDQ on the newly discovered brain I2-imidazoline sites, located mainly in mitochondria. Preincubation of rat cortical membranes with EEDQ (10(-8)-10(-5) M) markedly decreased (20-90%) the specific binding of the selective antagonist [3H]RX821002 to alpha 2-adrenoceptors without affecting that of [3H]idazoxan (in the presence of adrenaline) to I2-imidazoline sites. In EEDQ-pretreated membranes (10(-5) M, 30 min at 25 degrees C), the density of I2-imidazoline sites (Bmax = 80 +/- 4 fmol/mg of protein) was not different from that determined in untreated membranes in the presence of (10(-6) M (-)-adrenaline (Bmax = 83 +/- 4 fmol/mg of protein), and both densities were lower (24%, p < 0.05) than the total native density of [3H]idazoxan binding sites (Bmax = 107 +/- 6 fmol/mg of protein) (I2-imidazoline sites plus alpha 2-adrenoceptors). Treatment of rats with an optimal dose of EEDQ (1.6 mg/kg, i.p., for 2 h to 30 days) reduced maximally at 6 h (by 95 +/- 1%) the specific binding of [3H]-RX821002 to alpha 2-adrenoceptors, but also the binding of [3H]idazoxan to I2-imidazoline sites (by 44 +/- 5%). Pretreatment with yohimbine (10 mg/kg, i.p.) fully protected against EEDQ-induced alpha 2-adrenoceptor inactivation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A Miralles
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
39
|
Miralles A, Ribas C, Olmos G, García-Sevilla JA. No effect of genetic obesity and mazindol on imidazoline I2 binding sites in the brain of Zucker rats. Eur J Pharmacol 1993; 243:305-8. [PMID: 8276084 DOI: 10.1016/0014-2999(93)90191-j] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The density and affinity states of imidazoline I2 binding sites as well as the density of alpha 2-adrenoceptors were quantitated in the brain of lean and obese Zucker rats. No significant differences were obtained between Zucker phenotypes for these receptors in the cerebral cortex and hypothalamus. Moreover, chronic treatment with the anorexic imidazoline derivative, mazindol, did not alter the density of brain imidazoline I2 binding sites. It is concluded that this genetic model of obesity is not associated with abnormal imidazoline I2 binding sites.
Collapse
Affiliation(s)
- A Miralles
- Department of Fundamental Biology and Health Science, University of Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
40
|
Ugedo L, Garro MA, Pineda J, Giralt MT, Miralles A, Olmos G, García-Sevilla JA, Menargues A, Obach R. Acute and chronic effects of reserpine on biochemical and functional parameters of central and peripheral alpha 2-adrenoceptors. Eur J Pharmacol 1993; 239:149-57. [PMID: 7901027 DOI: 10.1016/0014-2999(93)90988-t] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The specific binding of the agonist, [3H]UK 14304, and of the antagonist, [3H]RX 821002, to rat brain membranes, as well as clonidine-induced mydriasis, clonidine-induced inhibition and idazoxan-induced stimulation of brain 3,4-dihydroxyphenylalanine (DOPA) synthesis, and clonidine and UK 14304-induced inhibition of twitch responses in the vas deferens were used to evaluate the affinity and sensitivity of central and peripheral alpha 2-adrenoceptors after various treatments with reserpine. Treatment with reserpine (0.25 mg/kg s.c., every 48 h) for 4, 11 and 18 days induced consistent and significant increases in the affinity (KD values) of [3H]UK 14304 for the cortical alpha 2-adrenoceptor with no change in receptor density. Chronic treatment with reserpine also resulted in a greater affinity of (-)-adrenaline for the high-affinity state of the alpha 2-adrenoceptor when the catecholamine competed with the binding of [3H]RX 821002 to cortical membranes. In line with these radioligand binding data, various functional responses mediated by central and peripheral alpha 2-adrenoceptors were found to be potentiated after repeated treatment with reserpine. Thus, the inhibitory alpha 2-autoreceptor that modulates the synthesis of brain noradrenaline and the central postsynaptic inhibitory alpha 2-adrenoceptor that induces mydriasis displayed greater responses in vivo after chronic treatment with reserpine. Short-term and chronic treatments with reserpine also increased the sensitivity of peripheral presynaptic alpha 2-adrenoceptors in the vas deferens.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- L Ugedo
- Department of Pharmacology, Faculty of Medicine, University of the Basque Country, Leioa, Bizkaia, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Olmos G, Miralles A, García-Sevilla JA, Giralt MT, Pineda J, Asier Garro M, Ugedo L, Menargues A, Obach R. Acute and chronic effects of cholinesterase inhibitors and pilocarpine on the density and sensitivity of central and peripheral alpha 2-adrenoceptors. Eur J Pharmacol 1993; 236:467-76. [PMID: 8102972 DOI: 10.1016/0014-2999(93)90486-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The specific binding of the agonists [3H]clonidine and [3H]UK 14304 (bromoxidine) and of the antagonist [3H]RX 821002 (2-metoxy idazoxan) to rat brain membranes, as well as clonidine-induced mydriasis, clonidine-induced inhibition of brain (3,4-dihydroxyphenylalaninme) DOPA synthesis and clonidine-induced inhibition of twitch responses in the vas deferens, was used to evaluate the density and sensitivity of central and peripheral alpha 2-adrenoceptors after prolonged activation of the cholinergic system. Acute (12 h), short-term (4 days) or chronic (7-18 days) treatment with the cholinesterase inhibitors neostigmine (0.1 mg/kg), physostigmine (0.1 mg/kg) and diisopropylfluorophosphate (2 mg/kg) and with the muscarinic receptor agonist pilocarpine (10 mg/kg) did not alter the density of brain alpha 2-adrenoceptors. In contrast, various functional responses mediated by central and peripheral alpha 2-adrenoceptors were potentiated after the repeated treatments. Thus, the inhibitory alpha 2-autoreceptor that modulates the synthesis of brain noradrenaline and the central postsynaptic inhibitory alpha 2-adrenoceptor that induces mydriasis displayed greater responses in vivo after chronic treatment with neostigmine or pilocarpine. These treatments also increased the sensitivity of peripheral presynaptic alpha 2-adrenoceptors in the vas deferens. The results indicate that prolonged activation of central and peripheral cholinergic pathways results in up-regulation of alpha 2-adrenoceptor function without apparent increases in receptor density.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Olmos G, Gabilondo AM, Miralles A, Escriba PV, García-Sevilla JA. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Br J Pharmacol 1993; 108:597-603. [PMID: 8385528 PMCID: PMC1908014 DOI: 10.1111/j.1476-5381.1993.tb12848.x] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
1. The binding of [3H]-idazoxan in the presence of 10(-6) M (-)-adrenaline was used to quantitate non-adrenoceptor idazoxan binding sites (NAIBS) in the rat brain after treatment with various psychotropic drugs. 2. Chronic treatment (14 days) with the monoamine oxidase (MAO) inhibitors clorgyline (0.3-10 mg kg-1, i.p.) and pargyline (10 mg kg-1, i.p.), but not with Ro 41-1049 (1 mg kg-1, i.p.), markedly decreased (30-50%) the density of NAIBS in the cerebral cortex without any apparent change in the affinity of the radioligand. 3. Acute (1 day) and/or chronic treatments (14 days) with other psychotropic drugs such as desipramine (3 mg kg-1, i.p.), cocaine (10 mg kg-1, i.p.), reserpine (0.12 mg kg-1, s.c.), haloperidol (1 mg kg-1, i.p.) and diazepam (10 mg kg-1, i.p.) did not alter the density of NAIBS in the cerebral cortex. 4. In vitro, the propargylamines clorgyline, pargyline and deprenyl displaced the binding of [3H]-idazoxan to NAIBS from two distinct sites, but only clorgyline displayed an apparent very high affinity for a relevant population of NAIBS (KiH = 40 pM; KiL = 10.6 microM). The structurally diverse MAO inhibitors Ro 16-6491 (selective for MAO-B) and Ro 41-1049 (selective for MAO-A), as well as the other psychotropic drugs (desipramine, cocaine, reserpine and haloperidol) displaced the binding of [3H]-idazoxan to NAIBS monophasically and with very low potencies. As expected, the MAO inhibitors clorgyline and Ro 41-1049 displaced the binding of [3H]-Ro 41-1049 to MAO-A monophasically and with high potencies (Ki values: 0.18 nM and 22 nM, respectively). In contrast, idazoxan displayed very low affinity (Ki =40 microM) against the binding of pH]-Ro 41-1049 to MAO-A. These results disprove a direct interaction between [3H]-idazoxan and the enzyme MAO.5. Preincubation of cortical membranes with clorgyline (10-9M or 10-6 M for 30 min) or pargyline(10-6 M or 10-5M for 30 min), reduced by 30-50% and by 17-30%, respectively, the total density of NAIBS without any apparent change in the affinity of the radioligand. Preincubation with 10-6M clorgyline did not alter the affinity of cirazoline for the two populations of NAIBS, but reduced by 60%the binding of [3H]-idazoxan to the high affinity site without affecting the binding of the radioligand to the low affinity site. These results indicate that the two MAO inhibitors irreversibly block the binding of[3H]-idazoxan to NAIBS.6. In vivo, however, various acute treatments with clorgyline (1-20 mg kg-1, i.p.) for different time intervals (6-48 h) did not alter the density of NAIBS. In vivo, only very high doses of clorgyline (40 and 80 mg kg-1, i.p.) induced modest decreases (21-28%) in the density of NAIBS in the cerebral cortex.7. Together the results indicate that the irreversible binding of clorgyline and pargyline to NAIBSfound in vitro does not fully explain the marked decreases in the density of NAIBS found in vivo after the chronic treatments. It is suggested that the down-regulation of NAIBS induced in vivo by clorgyline and pargyline, through a direct or indirect mechanism, may have functional implications.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | | | |
Collapse
|
43
|
Miralles A, Olmos G, Sastre M, Barturen F, Martin I, Garcia-Sevilla JA. Discrimination and pharmacological characterization of I2-imidazoline sites with [3H]idazoxan and alpha-2 adrenoceptors with [3H]RX821002 (2-methoxy idazoxan) in the human and rat brains. J Pharmacol Exp Ther 1993; 264:1187-97. [PMID: 8095548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The alpha-2 adrenoceptor antagonist idazoxan has been shown to also recognize with high affinity nonadrenoceptor sites (I2-imidazoline sites). In contrast, the 2-methoxy derivative of idazoxan, 2-methoxy idazoxan (RX821002), binds almost exclusively to alpha-2 adrenoceptors. The purpose of this study was to assess and extend the pharmacological characterization of I2-imidazoline sites and alpha-2 adrenoceptors in the human and rat brains. Competition studies with several imidazoli(di)ne/guanidine drugs and other nonrelated structures were performed in cortical membranes against [3H]idazoxan (4 nM in the presence of 10(-6) M I-epinephrine to prevent binding to alpha-2 adrenoceptors) or [3H]RX821002 (1 nM). Drugs such as cirazoline, guanoxan, naphazoline, tolazoline, clonidine, bromoxidine (UK 14,304) and phenylbiguanide displaced [3H]idazoxan from two distinct binding sites, which suggested the existence of two affinity states for I2-imidazoline sites that were not modulated by MgCl2 or the nucleotide analog guanylyl-5'-imido-diphosphate. Binding affinities at the low-affinity site (KiL) were consistently more than 2 orders of magnitude lower than binding affinities at the high-affinity site (KiH), and there was a good correlation between KiH and KiL values for a given drug in the human (r = 0.89) and rat (r = 0.92) brains. For 18 to 22 drugs, the Ki values in the human brain correlated well with the corresponding Ki values in the rat brain both for I2-imidazoline sites (r = 0.94) and alpha-2 adrenoceptors (r = 0.97). However, the Ki values for I2-imidazoline sites did not correlate with the Ki values for alpha-2 adrenoceptors in human and rat brains. The order of drug potency for the I2-imidazoline sites was: guanoxan (1.3 nM) approximately cirazoline > idazoxan approximately naphazoline > clonidine > phentolamine > RX821002 > (8aR, 12aS, 13aS)-3-methoxy-12-methanesulfonyl-5,6,8a,9,10,11,12,12a,13,13a- decahydro-8H-isoquino[2,1-g]-naphthyridine (RS 15385-197) (> 10 microM). In contrast, the potencies at the alpha-2 adrenoceptor were: RS 1538-197 (0.3 nM) > RX821002 > clonidine > phentolamine > idazoxan approximately naphazoline > guanoxan approximately cirazoline (307 nM). The results demonstrate that I2-imidazoline sites (labeled by [3H]idazoxan) and alpha-2 adrenoceptors are different pharmacological entities with similar characteristics in the human and rat brains. In both species, I2-imidazoline sites are markedly heterogeneous in nature.
Collapse
MESH Headings
- Adrenergic alpha-Antagonists/metabolism
- Adult
- Animals
- Brain/metabolism
- Brain Chemistry
- Dioxanes/metabolism
- Epinephrine/pharmacology
- Female
- Humans
- Idazoxan
- Imidazoline Receptors
- In Vitro Techniques
- Male
- Middle Aged
- Rats
- Rats, Sprague-Dawley
- Receptors, Adrenergic, alpha/analysis
- Receptors, Adrenergic, alpha/drug effects
- Receptors, Adrenergic, alpha/metabolism
- Receptors, Drug/analysis
- Receptors, Drug/drug effects
- Receptors, Drug/metabolism
Collapse
Affiliation(s)
- A Miralles
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Spain
| | | | | | | | | | | |
Collapse
|
44
|
Olmos G, Miralles A, Barturen F, Garcia-Sevilla JA. Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment. J Pharmacol Exp Ther 1992; 260:1000-7. [PMID: 1545372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
The binding of [3H]idazoxan in the presence of l-epinephrine was used to characterize and quantitate imidazoline receptors in the brain of spontaneously hypertensive (SHR), normotensive Wistar-Kyoto (WKY) and Sprague-Dawley (SD) rats before and after chronic imidazoline drug treatment. In the cerebral cortex of WKY and SHR rats, the rank order of potency of imidazoli(di)ne drugs (cirazoline greater than idazoxan greater than naphazoline greater than clonidine much greater than RX821002) competing with [3H]idazoxan showed the specificity for an imidazoline receptor which also appeared heterogeneous in nature. In SHR rats, the density of imidazoline receptors (hypothalamus greater than medulla oblongata greater than cerebral cortex) and proportion of high- and low-affinity sites for the receptor were not different from those in WKY and SD rats, suggesting that the receptor itself is not altered in hypertension. However, chronic treatment with idazoxan and cirazoline (10 and 1 mg/kg, i.p., every 12 h for 7 days) consistently increased (about 35%) the density of imidazoline receptors in the brain of WKY and SD, but not in SHR rats. A similar treatment with RX821002, the 2-methoxy analog of idazoxan, which is a highly selective alpha-2 adrenoceptor antagonist, did not increase the density of brain imidazoline receptors. Moreover, the up-regulation of these receptors induced by cirazoline was still present after alkylation of the alpha-2 adrenoceptors with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. The lack of regulation by idazoxan and cirazoline of the density of imidazoline receptors in the brain of SHR rats suggests the existence of a relevant abnormality in the adaptive process of these receptors in this genetic model of hypertension.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
45
|
Olmos G, Miralles A, Barturen F, García-Sevilla JA. Decreased density and sensitivity of alpha 2-adrenoceptors in the brain of spontaneously hypertensive rats. Eur J Pharmacol 1991; 205:93-6. [PMID: 1667385 DOI: 10.1016/0014-2999(91)90776-m] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The specific binding of the agonist [corrected], [3H]clonidine, to neural membranes and clonidine-induced mydriasis were used to evaluate the density and sensitivity [corrected] of alpha 2-adrenoceptors in the brain of spontaneously hypertensive rats (SHR) and sex- and age-matched normotensive Wistar-Kyoto (WKY) rats. In hypertensive rats (SHR) the density of alpha 2-adrenoceptors was reduced in the cerebral cortex, hypothalamus and medulla oblongata (20-27%), as was the dose-pupillary response curve for clonidine (1.8-fold). The results demonstrated that this model of genetic hypertension is associated with desensitization of alpha 2-adrenoceptors in the brain.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
46
|
Olmos G, Miralles A, Barturen F, García-Sevilla JA. Repeated idazoxan increases brain imidazoline receptors in normotensive (WKY) but not in hypertensive (SHR) rats. J Neurochem 1991; 57:1811-3. [PMID: 1681037 DOI: 10.1111/j.1471-4159.1991.tb06386.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The specific binding of [3H]idazoxan in the presence of 10(-6) M (-)-adrenaline was used to evaluate the density of imidazoline receptors in the brain of spontaneously hypertensive (SHR) rats and sex- and age-matched normotensive Wistar-Kyoto (WKY) rats. In SHR rats the density of imidazoline receptors (cerebral cortex, hypothalamus, and medulla oblongata) was not different from that in normotensive (WKY) rats. However, repeated treatment with idazoxan consistently increased (23-80%) the density of imidazoline receptors in the various brain regions of WKY rats but not in SHR rats. In normotensive Sprague-Dawley rats, repeated treatment with the imidazoline drugs idazoxan and cirazoline also increased (33-37%) the density of imidazoline receptors in the cerebral cortex. The lack of regulation by idazoxan of the density of imidazoline receptors in the brain of SHR rats might reflect the existence of a relevant abnormality of these receptors in this genetic model of hypertension.
Collapse
Affiliation(s)
- G Olmos
- Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
| | | | | | | |
Collapse
|
47
|
Abstract
We have analyzed the developmental properties of kainate receptors in cerebellar membranes prepared from chick and rat, two vertebrate species with contrasting patterns of functional maturation. Single populations of binding sites have been characterized in the avian and rodent membranes with apparent dissociation constants (Kd) in the 210-280 nM and 40-55 nM ranges, respectively; the number of binding sites (Bmax) increases with age in both species, reaching a maximum of 187 pmol/mg in the case of 10-day chicks vs. 1.28 pmol/mg in 75-day rats. The ontogenetic profiles of kainate receptors in chick and rat cerebella are in consonance with the patent differences in motor development at birth.
Collapse
Affiliation(s)
- A Miralles
- Laboratorio de Biología Celular, Universidad de las Islas Baleares, Palma de Mallorca, Spain
| | | | | |
Collapse
|
48
|
Garcia-Segura LM, Olmos G, Robbins RJ, Hernandez P, Meyer JH, Naftolin F. Estradiol induces rapid remodelling of plasma membranes in developing rat cerebrocortical neurons in culture. Brain Res 1989; 498:339-43. [PMID: 2790487 DOI: 10.1016/0006-8993(89)91113-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Exo-endocytotic images and intramembrane particles were quantitatively assessed in freeze-fracture replicas from the plasma membrane of dispersed fetal rat cortical neurons (day 16 gestation) grown for 24 days in culture. The addition of 10(-10) M 17 beta-estradiol to the culture medium resulted in a significant increase in the numerical density of exo-endocytotic images within 1 min. A further increase of the number of exo-endocytotic images associated to a significant decrease in the number of intramembrane particles was observed in cells exposed for 10 min to 17 beta-estradiol. Similar results were observed when the cells were exposed to 17 beta-estradiol for 17 days. No effects on exo-endocytotic images and intramembrane particles were observed when 17 alpha-estradiol was added, instead of 17 beta-estradiol, to the cultures. These results indicate that physiological levels of 17 beta-estradiol can have rapid effects upon the ultrastructure of the neuronal membrane of developing cerebrocortical neurons.
Collapse
|
49
|
Abstract
Previous studies have shown that synaptic connections and organization of neuronal membranes are sexually dimorphic in the arcuate nucleus of developing and adult rats. These sex differences can be abolished by the perinatal androgenization of females. In this study the label-fracture method of Pinto da Silva and Kan was used in order to determine whether membrane sex differences are related to the glycoconjugates in neuronal plasma membranes. Six Sprague-Dawley female rats treated with testosterone on the day of birth, six control females injected with vehicle and six intact males were studied when they were 100 days old. The arcuate nucleus was dissected and incubated for 2 hours in a solution of 0.25 mg/ml concanavalin A, washed in buffer and incubated for 3 hours in a suspension of horseradish peroxidase-coated colloidal gold. Then, freeze-fracture replicas of the arcuate nucleus were prepared. Colloidal gold labeling was observed to be codistributed with intramembrane particles in the outer membrane face of the neuronal perikaryal plasma membrane. The numerical density of small (less than 10 nm) intramembrane particles and colloidal gold particles was significantly greater in control female membranes when compared to males or to androgenized females. The labeling was significantly reduced when the arcuate nucleus was incubated with concanavalin A in presence of 0.5 M methyl-alpha-manopyranoside. These findings indicate a sex difference in the density and distribution of glycoconjugates and intramembranous particles in the neuronal plasma membrane that is dependent on the perinatal levels of sex steroids and is concordant with, and could be the cause of, sex differences in the pattern of synaptic contacts.
Collapse
|
50
|
Abstract
1. A total particulate fraction of chick cerebellar membranes, obtained by a simple method, has been found to specifically bind [3H]kainic acid. Non-neuronal tissue, like chick liver, does not show any appreciable specific binding under the same experimental conditions. 2. Specific [3H]kainic acid binding to chick cerebellar membranes increases linearly with tissue concentration, reaches the binding equilibrium almost instantaneously and is pH and temperature dependent. 3. Specifically bound [3H]kainic acid is displaced by suitable concentrations of unlabelled kainic acid, L-glutamic acid and other excitatory amino acid analogues, both agonist and antagonist. This pharmacological pattern agrees with the general pharmacological properties of kainic acid receptors. 4. Saturation kinetic studies of kainic acid binding sites show one single binding mode with an apparent dissociation constant KD = 278 nM and a maximum number of binding sites of 187 pmoles/mg of protein. 5. In view of the mentioned data and the high amount of receptor sites found in chick cerebellar membranes, as compared with related values in rat cerebellum, we suggest that these receptors play a different physiological role or that they have a different cellular localization in chick and rat cerebellum.
Collapse
Affiliation(s)
- A Miralles
- Department de Biologia i Ciències de la Salut, Universitat de les Illes Balears, Ciutat de Mallorca, Spain
| | | |
Collapse
|